Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Ondrejka, I."'
Publikováno v:
Journal of Inflammation Research, Vol Volume 15, Pp 5959-5976 (2022)
Nikola Ferencova,1 Zuzana Visnovcova,1 Igor Ondrejka,2 Dana Funakova,2 Igor Hrtanek,2 Simona Kelcikova,3 Ingrid Tonhajzerova4 1Biomedical Centre Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovak Republ
Externí odkaz:
https://doaj.org/article/2a5f2038b21749679d13e854803511da
Autor:
Hrtanek, I., Bittsansky, M., Tonhajzerova, I., Grendar, M., Oppa, M., Cesnekova, D., Farsky, I., Hutka, P., Dobrota, D., Zelenak, K., Ondrejka, I. *
Publikováno v:
In The European Journal of Psychiatry April-June 2021 35(2):92-98
Publikováno v:
Acta Medica Martiniana, Vol 19, Iss 1, Pp 30-37 (2019)
Attention deficit/hyperactivity disorder (ADHD) is one of the most frequently seen mental disorders in children with an increasing risk for other mental disorders. ADHD represents a primary biological dysfunction of the central nervous system, such a
Externí odkaz:
https://doaj.org/article/8061f13ff1964bb2962becfc6b84315a
Publikováno v:
Acta Medica Martiniana, Vol 19, Iss 1, Pp 22-29 (2019)
Introduction: With an increasing prevalence of major depressive disorder (MDD) in population there is a particular interest in finding a suitable biomarker for diagnosis and prognosis of the disease. Many studies have shown that MDD is linked to a sy
Externí odkaz:
https://doaj.org/article/99304f7ac82b45a9a08cc998db97671e
Publikováno v:
Acta Medica Martiniana, Vol 17, Iss 3, Pp 16-23 (2017)
Background: Autism spectrum disorder (ASD) is a serious neurodevelopmental disorder associated with autonomic nervous system (ANS) abnormalities. Moreover, at least 50% of children with ASD suffer from other comorbid diseases such as anxiety, depress
Externí odkaz:
https://doaj.org/article/81396788ce71470c895d0e0003948d71
Publikováno v:
European Pharmaceutical Journal, Vol 64, Iss 1, Pp 13-16 (2017)
Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin reuptake inhibition. Atypical antipsychotics, such as olanzapine, used in the augmentation of antidepressants causes n
Externí odkaz:
https://doaj.org/article/0da0df4b3d3b4aee988a619f43916977
Publikováno v:
European Pharmaceutical Journal, Vol 63, Iss 1, Pp 29-32 (2016)
Attention-Deficit/Hyperactivity Disorder (ADHD) is connected with high level of psychiatric comorbidity in paediatric population. Depressive disorder is common comorbid disorder co-existing with ADHD. Atomoxetine is worldwide approved for treatment o
Externí odkaz:
https://doaj.org/article/5ef7c8d7a9b84ac0a90691576d7a6a4b
Publikováno v:
European Pharmaceutical Journal, Vol 63, Iss 1, Pp 25-28 (2016)
In the previous research at Jessenius Faculty of Medicine in Martin has been studied depression and its treatment from the aspects of the quality of life and functioning of the patients, as well as comparing the efficacy and safety of venlafaxine ver
Externí odkaz:
https://doaj.org/article/ba05962663ee4304b2f7d357feaf7455
Publikováno v:
Acta Medica Martiniana, Vol 16, Iss 2, Pp 44-48 (2016)
Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin re-uptake inhibition. It shows antidepressant, anxiolytic and cognitive effects during the treatment of major depressi
Externí odkaz:
https://doaj.org/article/b7a834a8d0e74e6c83948a77b554d063
Publikováno v:
European Pharmaceutical Journal, Vol 64, Iss 1, Pp 1-3 (2017)
Depressive disorder is one of the most common and serious psychiatric diagnosis in paediatric population, often connected with suicidal risk. In recent years, fluoxetine monotherapy is the gold standard in acute phase of depression treatment in child
Externí odkaz:
https://doaj.org/article/902ddcfcfc04487e981613202fa853f7